# An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy

> **NCT02346461** · PHASE2 · COMPLETED · sponsor: **National Human Genome Research Institute (NHGRI)** · enrollment: 12 (actual)

## Conditions studied

- GNE Myopathy

## Interventions

- **DRUG:** ManNAc
- **DRUG:** ManNAc

## Key facts

- **NCT ID:** NCT02346461
- **Lead sponsor:** National Human Genome Research Institute (NHGRI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-05
- **Primary completion:** 2017-12-30
- **Final completion:** 2018-11-15
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02346461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02346461, "An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02346461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*